Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 51

  1. Cat.No. Product Name Information/Activity
  2. BCC7255 UBP 296 745055-86-1 UBP 296 chemical structure
  3. BCC7172 UBP 301 569371-10-4 UBP 301 chemical structure
  4. BCC7256 UBP 302 UBP 302 is a potent and selective GLUK5-subunit containing kainate receptor antagonist (apparent Kd=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects. UBP 302 chemical structure
  5. BCC6052 UBP 310 902464-46-4 UBP 310 chemical structure
  6. BCN6291 Arctigenin Arctigenin is a lignan found in certain plants of the Asteraceae; it has shown antiviral and anticancer effects in glass; it is the aglycone of arctiin. Arctigenin chemical structure
  7. BCC5883 PDZ1 Domain inhibitor peptide 1315378-73-4 PDZ1 Domain inhibitor peptide chemical structure
  8. BCC6634 N-Acetylglycyl-D-glutamic acid 135701-69-8 N-Acetylglycyl-D-glutamic acid chemical structure
  9. BCC6612 L-AP6 78944-89-5 L-AP6 chemical structure
  10. BCC7400 L-BMAA hydrochloride 16012-55-8 L-BMAA hydrochloride chemical structure
  11. BCC6585 2,4-Dihydroxyphenylacetyl-L-asparagine 111872-98-1 2,4-Dihydroxyphenylacetyl-L-asparagine chemical structure

Items 501 to 510 of 709 total